SG11201912195TA - Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies - Google Patents

Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Info

Publication number
SG11201912195TA
SG11201912195TA SG11201912195TA SG11201912195TA SG11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA
Authority
SG
Singapore
Prior art keywords
synucleinopathies
formulations
alpha
treatment
terminal end
Prior art date
Application number
SG11201912195TA
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
United Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Neuroscience filed Critical United Neuroscience
Publication of SG11201912195TA publication Critical patent/SG11201912195TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
SG11201912195TA 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies SG11201912195TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521287P 2017-06-16 2017-06-16
PCT/US2018/037938 WO2018232369A1 (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
SG11201912195TA true SG11201912195TA (en) 2020-01-30

Family

ID=64659951

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912195TA SG11201912195TA (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Country Status (10)

Country Link
US (1) US20210138049A1 (https=)
EP (1) EP3638298A4 (https=)
JP (3) JP2021508672A (https=)
KR (2) KR20200054938A (https=)
AU (2) AU2018283510B8 (https=)
BR (1) BR112019026707A2 (https=)
CA (1) CA3067231A1 (https=)
MX (1) MX2019015286A (https=)
SG (1) SG11201912195TA (https=)
WO (1) WO2018232369A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CA3079236A1 (en) 2017-10-27 2019-05-02 United Neuroscience Tau peptide immunogen constructs
BR112021012668A2 (pt) 2018-12-28 2021-12-28 United Biomedical Inc Imunógenos de peptídeos que possuem como alvo interleucina 6 (il-6) e formulações dos mesmos para imunoterapia de doenças impactadas pela desregulação de il-6
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
JP2023536497A (ja) * 2020-08-04 2023-08-25 エイシー イミューン ソシエテ アノニム 免疫原性化合物
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
EP4357354A1 (en) 2021-06-18 2024-04-24 Sumitomo Pharma Co., Ltd. Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide
EP4395894A4 (en) * 2021-09-01 2025-08-06 Vaxxinity Inc METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US20120142902A1 (en) * 2007-02-23 2012-06-07 The Regents Of The University Of California Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
US12156912B2 (en) * 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
CA2885924C (en) * 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US20170184612A1 (en) * 2014-04-09 2017-06-29 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
WO2015179867A1 (en) * 2014-05-23 2015-11-26 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease

Also Published As

Publication number Publication date
US20210138049A1 (en) 2021-05-13
JP2023082018A (ja) 2023-06-13
RU2020101121A3 (https=) 2021-10-15
EP3638298A1 (en) 2020-04-22
EP3638298A4 (en) 2021-05-05
WO2018232369A1 (en) 2018-12-20
JP2025090637A (ja) 2025-06-17
JP2021508672A (ja) 2021-03-11
MX2019015286A (es) 2020-08-17
AU2018283510A1 (en) 2020-01-16
AU2018283510B2 (en) 2025-06-26
RU2020101121A (ru) 2021-07-16
CA3067231A1 (en) 2018-12-20
KR20200054938A (ko) 2020-05-20
BR112019026707A2 (pt) 2020-06-30
KR20240150813A (ko) 2024-10-16
AU2018283510B8 (en) 2025-09-18
AU2025238083A1 (en) 2025-10-23
JP7732676B2 (ja) 2025-09-02

Similar Documents

Publication Publication Date Title
SG11201912195TA (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
IL276464A (en) Methods and preparations for administering therapeutic protein
IL275777A (en) Improved peptide drugs for the treatment of NASH and other disorders
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
HUE057083T2 (hu) C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
EP3829597A4 (en) TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL290520A (en) Medicinal peptides
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
IL285144A (en) Medicinal peptides
HUE059500T2 (hu) Aminosavakat tartalmazó készítmények elhízás kezelésében történõ alkalmazásra
IL281513A (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
EP3697914C0 (en) VECTORS FOR TREATMENT OF FRIEDREICH'S AAXIA
EP3638204C0 (en) TPX-100 PEPTIDE INTENDED TO REDUCE KNEE JOINT PAIN
IL277734A (en) Application of short PEDF-derived peptides in the treatment of osteoarthritis
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
EP3628048A4 (en) PEPTIDES FOR CANCER TREATMENT
ZA202100587B (en) Peptide compounds and therapeutic uses of same
IL282519A (en) Peptide fragments for the treatment of diabetes
PL3416677T3 (pl) Kompozycja farmaceutyczna obejmująca rekombinowany hgh do leczenia niedoboru hormonu wzrostu
IL275690A (en) Nanoparticles for targeted delivery of therapeutic polypeptides
ZA202100880B (en) Short cyclic peptides for the treatment of graves' disease
EP3648789C0 (en) MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY
IL325751A (en) Injection techniques for treating cellulite